Kynurenic Acid in the Digestive System—New Facts, New Challenges

This review provides information on the most recent findings concerning presence, origin, and role of kynurenic acid (KYNA), a tryptophan metabolite, in the digestive system. KYNA is an antagonist of both the ionotropic glutamate receptors and the alpha7 nicotinic acetylcholine receptor, as well as an agonist of G-protein coupled GPR35 receptor. Since the GPR35 receptor is mainly present in the gastrointestinal tract, researchers have concentrated on the digestive system in recent years. They have found that KYNA content increases gradually and significantly along the gastrointestinal tract. Interestingly, the concentration of KYNA in the lumen is much higher than in the wall of intestine. It has been documented that KYNA may have a positive influence on the number of pathologies in the gastrointestinal tract, in particular ulcers, colon obstruction, or colitis. Future studies might determine whether it is advisable to supplement KYNA to a human organism.

[1]  J. Bralley,et al.  Analysis of urinary aromatic acids by liquid chromatography tandem mass spectrometry. , 2008, Biomedical chromatography : BMC.

[2]  K. Markides,et al.  Quantitation of tryptophan, kynurenine and kynurenic acid in human plasma by capillary liquid chromatography-electrospray ionization tandem mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  S. Erhardt,et al.  Kynurenic acid and schizophrenia. , 2003, Advances in experimental medicine and biology.

[4]  P. Milart,et al.  [Kynurenic acid concentration in blood and urine during normal pregnancy]. , 1998, Ginekologia polska.

[5]  W. Zgrajka,et al.  Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro , 2006, Rheumatology International.

[6]  B. Brew,et al.  The kynurenine pathway in brain tumor pathogenesis. , 2012, Cancer research.

[7]  R. Schwarcz,et al.  Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. , 2010, Schizophrenia bulletin.

[8]  M. Baraldi,et al.  Changes in Kynurenic, Anthranilic, and Quinolinic Acid Concentrations in Rat Brain Tissue During Development , 2001, Neurochemical Research.

[9]  S. Furlanetto,et al.  Set-up and validation of an adsorptive stripping voltammetric method for kynurenic acid determination in human urine. , 1998, Journal of pharmaceutical and biomedical analysis.

[10]  K. Blennow,et al.  Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia , 2005, Schizophrenia Research.

[11]  J. Kew,et al.  Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels , 2009, Neuropharmacology.

[12]  R. Davis,et al.  Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor. , 1995, Journal of medicinal chemistry.

[13]  B. Kepplinger,et al.  Age-Related Increase of Kynurenic Acid in Human Cerebrospinal Fluid – IgG and β2-Microglobulin Changes , 2005, Neurosignals.

[14]  J. M. Price,et al.  The conversion of kynurenic acid to quinaldic acid by humans and rats. , 1956, Journal of Biological Chemistry.

[15]  K. Mawatari,et al.  Fluorometric determination of urinary kynurenic acid by flow injection analysis equipped with a "bypass line". , 1990, Analytical biochemistry.

[16]  F. Moroni,et al.  Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery , 2012, Journal of Neural Transmission.

[17]  G. Giovannoni,et al.  Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients , 2002, Neuroscience Letters.

[18]  M. Raiteri,et al.  N‐methyl‐D‐aspartate autoreceptors respond to low and high agonist concentrations by facilitating, respectively, exocytosis and carrier‐mediated release of glutamate in rat hippocampus , 2007, Journal of neuroscience research.

[19]  P. Luchowski,et al.  Serum kynurenic acid positively correlates with cardiovascular disease risk factor, homocysteine: a study in stroke patients. , 2006, Pharmacological reports : PR.

[20]  J. Reagan,et al.  Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35* , 2006, Journal of Biological Chemistry.

[21]  P. Klivényi,et al.  Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. , 2012, Current topics in medicinal chemistry.

[22]  R. Schwarcz,et al.  Identification and quantification of kynurenic acid in human brain tissue , 1988, Brain Research.

[23]  G. Lombardi,et al.  Kynurenic acid is present in the rat brain and its content increases during development and aging processes , 1988, Neuroscience Letters.

[24]  K. Walczak,et al.  Kynurenic acid enhances expression of p21 Waf1/Cip1 in colon cancer HT-29 cells , 2012, Pharmacological reports : PR.

[25]  W. Turski,et al.  Intrapartum levels of endogenous glutamate antagonist‐kynurenic acid in amniotic fluid, umbilical and maternal blood , 1999 .

[26]  W. Zgrajka,et al.  Presence of kynurenic acid in food and honeybee products , 2008, Amino Acids.

[27]  B. Kepplinger,et al.  Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2-microglobulin changes. , 2005, Neuro-Signals.

[28]  W. Zgrajka,et al.  Potato- An Important Source of Nutritional Kynurenic Acid , 2012, Plant Foods for Human Nutrition.

[29]  K. Walczak,et al.  Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells , 2011, Scandinavian journal of gastroenterology.

[30]  T. Urbanik-Sypniewska,et al.  Effect of kynurenic acid on the viability of probiotics in vitro , 2011, Pharmacological reports : PR.

[31]  D. Nutt,et al.  Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome. , 2010, Nutrition research.

[32]  K. Ueda,et al.  Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. , 1992, The Journal of biological chemistry.

[33]  R. Schwarcz,et al.  Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges. , 2013, Biochemical pharmacology.

[34]  K. Shibata,et al.  Fate of Dietary Tryptophan in Young Japanese Women , 2012, International journal of tryptophan research : IJTR.

[35]  W. Turski,et al.  Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis , 2003, Acta neurologica Scandinavica.

[36]  N. Cairns,et al.  Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome. , 1996, Life sciences.

[37]  W. Zgrajka,et al.  High concentration of kynurenic acid in bile and pancreatic juice , 2009, Amino Acids.

[38]  G. Glavin,et al.  Kynurenic acid attenuates experimental ulcer formation and basal gastric acid secretion in rats. , 1989, Research communications in chemical pathology and pharmacology.

[39]  W. Zgrajka,et al.  Kynurenic acid content in anti-rheumatic herbs. , 2013, Annals of agricultural and environmental medicine : AAEM.

[40]  Gerard Clarke,et al.  Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort , 2009, BMC gastroenterology.

[41]  G. Glavin,et al.  Kynurenic acid protects against gastroduodenal ulceration in mice injected with extracts from poisonous atlantic shellfish , 1989, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[42]  D. Bleakman,et al.  Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro , 2004, Neuropharmacology.

[43]  J. Leklem Quantitative aspects of tryptophan metabolism in humans and other species: a review. , 1971, The American journal of clinical nutrition.

[44]  Q. Han,et al.  Kynurenine aminotransferase and glutamine transaminase K of Escherichia coli: identity with aspartate aminotransferase. , 2001, The Biochemical journal.

[45]  G. Lombardi,et al.  Presence of Kynurenic Acid in the Mammalian Brain , 1988, Journal of neurochemistry.

[46]  W. Zgrajka,et al.  Distribution, synthesis, and absorption of kynurenic acid in plants. , 2011, Planta medica.

[47]  Dingliang Zhu,et al.  Simultaneous determination of urinary tryptophan, tryptophan-related metabolites and creatinine by high performance liquid chromatography with ultraviolet and fluorimetric detection. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[48]  W. Zgrajka,et al.  Micromolar concentration of kynurenic acid in rat small intestine , 2008, Amino Acids.

[49]  M. Beal,et al.  Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. , 1990, Analytical biochemistry.

[50]  K. Yoshinari,et al.  Inhibitory effects of kynurenic acid, a tryptophan metabolite, and its derivatives on cytosolic sulfotransferases. , 2009, The Biochemical journal.

[51]  R. Schwarcz,et al.  The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications , 2001, The Journal of Neuroscience.

[52]  S. Erhardt,et al.  Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[53]  B. Brew,et al.  Correction: The kynurenine pathway in brain tumor pathogenesis (Cancer Research (2012) 72, (5649-5657)) , 2012 .

[54]  D. Pawlak,et al.  Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure. , 2003, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[55]  R. Schwarcz,et al.  Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases , 1995, Journal of the Neurological Sciences.

[56]  T. Chase,et al.  Intravenous administration of L-kynurenine to rhesus monkeys: Effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid , 1993, Neuropharmacology.

[57]  A. Ganong,et al.  Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus. , 1986, The Journal of pharmacology and experimental therapeutics.

[58]  P. Klivényi,et al.  The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection , 2009, Journal of the Neurological Sciences.

[59]  A. Richter,et al.  Increased levels of kynurenic acid in brains of genetically dystonic hamsters. , 1996, Brain research. Developmental brain research.

[60]  L. Vécsei,et al.  Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[61]  R. Schwarcz,et al.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[62]  D. Bakheet KYNURENIC ACID AS AN ADDITIONAL ENDOGENOUS ANTI-AGGREGATORY FACTOR , 2007 .

[63]  R. Tridgett,et al.  7‐クロルキヌレン酸はN‐メチル‐D‐アスパラギン酸受容体複合体のグリシン調節部位での選択的きっ抗物質である , 1988 .

[64]  C. Post,et al.  Brain concentrations of kynurenic acid after a systemic neuroprotective dose in the gerbil model of global ischemia , 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[65]  C. J. Omiecinski,et al.  Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[66]  H. Hansen,et al.  Screening of OATP1B1/3 and OCT1 inhibitors in cryopreserved hepatocytes in suspension. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[67]  T. Stone,et al.  Levels of purine, kynurenine and lipid peroxidation products in patients with inflammatory bowel disease. , 2003, Advances in experimental medicine and biology.

[68]  Hitoshi Yamamoto,et al.  Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children , 1995, Brain and Development.

[69]  W. Boron,et al.  Medical physiology : a cellular and molecular approach , 2002 .

[70]  H. Scharfman,et al.  Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro , 2000, Amino Acids.

[71]  L. Vécsei,et al.  N‐Methyl‐d‐aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[72]  G. Lynch,et al.  A Glycine Site Associated with N‐Methyl‐d‐Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists , 1989, Journal of neurochemistry.

[73]  L. Iversen,et al.  7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[74]  W. Turski,et al.  Kynurenic acid in human saliva--does it influence oral microflora? , 2006, Pharmacological reports : PR.

[75]  R. Schwarcz,et al.  Kynurenines in the mammalian brain: when physiology meets pathology , 2012, Nature Reviews Neuroscience.

[76]  Joint Fao Who Consultation Protein and amino acid requirements in human nutrition. , 2007, World Health Organization technical report series.

[77]  R. Beninger,et al.  Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid , 1997, Neuroscience.

[78]  P. Klivényi,et al.  Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease , 2005, Journal of the Neurological Sciences.